Direct-to-Consumer Biobanking Firm LifeVault Bio Raises $5.6M

Dec 17, 2019

|

NEW YORK – LifeVault Bio, a consumer-facing company offering personal biobanking services under the name GoodCell, said Tuesday that it has closed on $5.6 million in financing. That total includes $2.6 million in investments and a $3 million convertible note.

The Waltham, Massachusetts-based startup did not identify the investors or lender.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Analysis for the Long Term

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Pricey, But Available

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Pilot Cancer Testing Program for Taiwan

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

PLOS Papers on TB Resistance, Squamous Cell Carcinoma Risk, MicroRNAs in SCC

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.

Menu

Direct-to-Consumer Biobanking Firm LifeVault Bio Raises $5.6M

To read the full story....

Breaking News

Top Five Articles on GenomeWeb Last Week: Agilent, Hologic, Bio-Techne, and More

Bio-Rad Laboratories, Roche Enter Quality Control Partnership

FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

Fauna Bio Gets $373K NIH Grant to Study Animal Genomes for Potential Drug Targets

New Products Posted to GenomeWeb: Purigen Biosystems, Zymo Research, Qiagen, More

The Scan

Analysis for the Long Term

Pricey, But Available

Pilot Cancer Testing Program for Taiwan

PLOS Papers on TB Resistance, Squamous Cell Carcinoma Risk, MicroRNAs in SCC

What's Popular?

Spatial Omics Firms Use AGBT as Launchpad for New Tech

Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

Fulgent Genetics Aims to Use COVID-19 Testing Gains to Grow Clinical Sequencing Business

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Sponsorships